Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT

Vertex (VRTX) received FDA approval to expand Casgevy use to patients aged 2+ with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), marking a first for genetic therapies in both inherited blood disorders. The broader label supports a meaningful expansion in potential addressable patient population and strengthens the commercial outlook for Casgevy.

Analysis

Vertex (VRTX) received FDA approval to expand Casgevy use to patients aged 2+ with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), marking a first for genetic therapies in both inherited blood disorders. The broader label supports a meaningful expansion in potential addressable patient population and strengthens the commercial outlook for Casgevy.